Idiopathic Hyperaldosteronism, IHA
Conditions
Interventions
Surgical group:Patients will undergo surgical treatment.
Pharmacological group:Patients will initiate standard mineralocorticoid receptor antagonist (MRA) therapy, with spironolactone or eplerenone as the foundation. The dosage will be adjusted according to
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 or older, any gender; 2. Patients clinically diagnosed with PA, diagnosed based on an elevated plasma aldosterone/renin ratio (ARR), positive saline infusion test, or positive captopril test; after completing [18F]AlF-NOTA-Pentixather PET/CT scans, all patients should undergo medication washout during screening and AVS; 3. Imaging (thin-slice adrenal CT or MRI) suggests: normal bilateral adrenal morphology, bilateral diffuse hyperplasia, or bilateral small nodules (maximum diameter < 1.0 cm); 4. Surgical group can include IHA patients intolerant to medication or with significant side effects, or patients with a strong personal desire for surgery; 5. Patients who can understand the study, voluntarily participate, and sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Imaging shows a clear unilateral adrenal adenoma (diameter >= 1.0 cm); 2. Other definite causes of secondary hypertension (e.g., renal artery stenosis); 3. Severe heart, liver, or cerebrovascular disease, or surgical contraindications making surgery or anesthesia intolerable; 4. Severe renal dysfunction; 5. Pregnant or breastfeeding women, or women planning to become pregnant during the study; 6. Suspected or confirmed adrenal cortical carcinoma or pheochromocytoma; 7. Unable to comply with long-term follow-up; 8. Currently participating in other clinical trials; 9. History of prior adrenal surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| aldosterone;Clinical effective remission rate at 12 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| renin;serum potassium;blood pressure; | — |
Countries
China
Contacts
Public ContactNing Zhang
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed